A5025804381- Bone health and treatments
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- Management of metastatic bone disease
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Advanced Breast Cancer Therapies
- Prostate Cancer Treatment and Research
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Glioma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging and Pathology Studies
- Economic and Financial Impacts of Cancer
- Multiple Myeloma Research and Treatments
- Brain Metastases and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Chemotherapy-related skin toxicity
- Medical Imaging Techniques and Applications
Kantonsspital Graubünden
2016-2025
Spital Thurgau (Switzerland)
2012-2024
University of St. Gallen
2005-2024
Erasmus MC Cancer Institute
2024
Erasmus MC
2024
Swiss Group For Clinical Cancer Research
2006-2023
University of Zurich
2021
National Cancer Registration Service
2021
Kantonsspital Baden
2007-2019
Kantonsspital St. Gallen
2003-2019
This study compared denosumab, a fully human monoclonal anti-receptor activator of nuclear factor kappa-B ligand antibody, with zoledronic acid (ZA) for delaying or preventing skeletal-related events (SRE) in patients advanced cancer and bone metastases (excluding breast prostate) myeloma.Eligible were randomly assigned double-blind, double-dummy design to receive monthly subcutaneous denosumab 120 mg (n = 886) intravenous ZA 4 (dose adjusted renal impairment; n 890). Daily supplemental...
Background Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% patients. Treatment algorithms management common ipilimumab-induced AEs have lead reduction morbidity, e.g. due bowel perforations. However, spectrum less is expanding as ipilimumab increasingly applied. Stringent recognition will reduce drug-induced morbidity costs, thus, positively impact cost-benefit...
Circulating endothelial cells (CECs) as well bone-marrow-derived precursor (EPC) play an important role in neovascularisation and tumour growth. To study the impact of neoadjuvant chemotherapy on amounts CEC their cells, mature progenitors were quantified by flow cytometry peripheral blood breast cancer patients during anthracycline and/or taxane based subsequent surgery comparison to age-matched healthy controls. Cell numbers tested for correlation with serum levels angiopoietin-2,...
Twenty-one adult patients were randomised to receive ghrelin on days 1 and 8 placebo 4 11 or vice versa, given intravenously over a 60-min period before lunch: 10 received 2 microg kg(-1) (lower-dose) ghrelin; (upper-dose) ghrelin. Active total ghrelin, growth hormone (GH), insulin-like factor levels monitored at baseline (4-5 day 1), during treatment days, end of study (day 17/18). Drug-related adverse events (assessed by NCI-CTC-toxicity criteria cardiac examination) did not differ between...
Abstract BACKGROUND: In this study, the authors evaluated effect of denosumab versus zoledronic acid (ZA) on pain in patients with advanced breast cancer and bone metastases. METHODS: The prevention pain, reduction interference daily life activities, proportion requiring strong opioid analgesics were assessed a randomized, double‐blind, double‐dummy phase 3 study comparing ZA for preventing skeletal‐related events 2046 who had Patients completed Brief Pain Inventory‐Short Form at baseline...
Purpose Cholesterol-lowering medication (CLM) has been reported to have a role in preventing breast cancer recurrence. CLM may attenuate signaling through the estrogen receptor by reducing levels of estrogenic cholesterol metabolite 27-hydroxycholesterol. The impact endocrine treatment on and hypercholesterolemia per se counteract intended effect aromatase inhibitors. Patients Methods Breast International Group (BIG) conducted randomized, phase III, double-blind trial, BIG 1-98, which...
Olaparib, an oral PARP inhibitor, has shown antitumour activity as monotherapy in patients with germline BRCA1/2 (gBRCA)-mutated breast and ovarian cancer. This study evaluated olaparib capsules combination liposomal doxorubicin (PLD) advanced solid tumours (NCT00819221). Patients received 28-day cycles of olaparib, continuously (days 1–28) or intermittently 1–7), plus PLD (40 mg m−2, day 1); seven dose cohorts (50–400 bid) were explored to determine the recommended dose. Assessments...
This multicenter phase IB/II trial investigated cetuximab added to preoperative chemoradiotherapy for esophageal cancer.Patients with resectable, locally advanced cancer received two 3-week cycles of induction chemoimmunotherapy (cisplatin 75 mg/m(2) day 1, docetaxel 250 days 8,15 [400 loading dose]) followed by chemoimmunoradiation therapy (CIRT) and surgery. CIRT consisted 45 Gy radiotherapy (RT) plus concurrent cisplatin 25 weekly 5 weeks in cohort 1. If fewer than three seven patients...